RxDoctor Payments Data

Ashwin Nathan, MD

Interventional Cardiology · Philadelphia, PANPI 1346688827

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (34.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Edwards Lifesciences at 40.4% of the total.

$46,383in general payments, 2019–2025

Across 260 payments — averaging $178.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$19K
  • Medtronic$12K
  • Abiomed$10K
  • Abbott$2K
  • Boston Scientific$940
  • Inari Medical, Inc.$728
  • plus $2K from 11 others
$282,100in research payments, 2019–2025

Across 7 payments — averaging $40,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$197K
  • Boston Scientific$86K

What the payments were for

  • Consulting fees$4,2409%
  • Speaking & faculty fees$13,82030%
  • Travel & lodging$15,76934%
  • Food & beverage$12,55427%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,383 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$128,955
Medicare patients
282
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metoprolol Succinate18$315
Atorvastatin Calcium18$215
Rosuvastatin Calcium12$190
Amlodipine Besylate15$56

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →